



## Statement

TITLE

**Amryt Pharma Anti-Slavery and Human Trafficking  
Statement for Financial Year ending December 2022**

PAGE

**1 of 2**

### **Introduction**

This statement is made for the purposes of Section 54, Part 6 of the UK Modern Slavery Act 2015 and sets out the steps that Amryt Pharma have taken to ensure that modern slavery and human trafficking is not taking place in our supply chains or in any part of our business.

### **Our Business**

Amryt is a biopharmaceutical company dedicated to developing and delivering innovative new treatments to help improve the lives of patients with rare and debilitating diseases. A core belief at Amryt Pharma is that we operate on a foundation of responsibility, integrity and ethical practice. Amryt is committed to fostering and maintaining its strong ethical corporate culture both throughout its organisation and when dealing with our suppliers.

### **Our Supply Chain and Due Diligence**

Amryt's supply chain consists of supplier of goods and services required to conduct our clinical trials, drug development and drug distribution. As part of our global risk management strategy, Amryt performs pre-engagement due diligence on our suppliers. This includes screening of sanctions lists, debarment and adverse media. Suppliers are periodically re-screened to ensure any potential new findings are captured and acted upon.

### **Training**

All Amryt employees receive training on our Global Code of Conduct, as well as how to confidentially report ethical concerns through our hotline.

### **Our Employment practices**

Amryt has a dedicated talent acquisition team who, with the assistance of third-party providers, conduct background checks on all prospective employees, to include education, employment, national ID, criminal background and debarment checks. Amryt does not employ any one below the minimum employment age in the jurisdictions in which we operate.

### **Reporting**

Amryt is committed to ensuring a speak up culture that encourages compliance, openness and accountability. Amryt actively supports employees raising concerns via dedicated escalation channels and through our confidential reporting hotline (Amryt's Ethics Line) if they believe anything illegal or unethical is taking place. Ethics Line is also available to our suppliers and other third parties with details provided in the Global Supplier Code of Conduct.

Amryt has a strict policy of non-retaliation and thoroughly investigates all concerns raised on an impartial and confidential basis.

### **Accountability**

At Amryt, employees are responsible for:

- adhering to the values and standards contained in our Global Code of Ethical Conduct;
- complying with relevant company policies;
- and for raising concerns if they believe that values and standards are not being met.



## Statement

TITLE

**Amryt Pharma Anti-Slavery and Human Trafficking  
Statement for Financial Year ending December 2022**

PAGE

**2 of 2**

Violations may result in a variety of corrective actions and in some cases may result in disciplinary action up to and including termination of employment. Amryt hold our suppliers accountable for meeting their contractual obligations with Amryt, including commitments that are made with regard to our Global Supplier Code of Conduct and regulatory compliance. Contract non-compliance can result in termination of the business relationship with the supplier and exclusion from future business with Amryt.

A handwritten signature in black ink, appearing to read "Joe Wiley", is written over a solid black horizontal line.

Dr. Joe Wiley, Chief Executive Officer